FDA Rejects Tenapanor for Control of Phosphorus in Kidney Disease FDA Rejects Tenapanor for Control of Phosphorus in Kidney Disease

An additional trial showing a ' clinically relevant treatment effect ' needed for approval in patients with kidney disease on dialysis, says the FDA in response to a new drug application.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Source Type: news